William G. Wierda, MD, PhD, on Using Venetoclax in CLL
Posted: Monday, August 5, 2019
What steps do you take to prevent tumor-lysis syndrome associated with targeted agents in CLL such as idelalisib, ibrutinib, and venetoclax?
Chronic Lymphocytic Leukemia Coverage from Every Angle
